Fortner RT et al. – Based on the current review, it was concluded that panels of autoantibodies (AAbs) may eventually reach sufficient diagnostic discrimination to allow earlier detection of disease as a complement to existing markers and transvaginal ultrasound.

Methods

• A total of 29 studies, including 85 AAbs, were reviewed.

Results

• The highest sensitivities for individual AAbs were reported for RhoGDI-AAbs (89.5%) and TUBA1C-AAbs (89%); however, the specificities were relatively low (80% and 75%, respectively).
• High sensitivities at high specificities were reported for HOXA7-AAbs for detection of moderately differentiated ovarian tumors (66.7% sensitivity at 100% specificity) and IL8-AAbs in stage I–II ovarian cancer (65.5% sensitivity at 98% specificity).
• A panel of 11 AAbs (ICAM3, CTAG2, p53, STYXL1, PVR, POMC, NUDT11, TRIM39, UHMK1, KSR1, and NXF3) had 45% sensitivity at 98% specificity for serous ovarian cancer, when at least 2 AAbs were above 95% specificity.
• The data suggest AAb markers improve diagnostic discrimination when combined with markers, such as CA125 and HE4.